| Abstrakt: |
Introduction: Alzheimer's disease is one of the leading causes of dementia. In this disease, short-term memory impairment occurs first, which leads to functional and behavioral disorders. The first development in Alzheimer's disease is the accumulation of beta-amyloid in the brain, which plays an important role in increasing oxidative stress. Oxidative stress is an important pathological factor in neurological diseases, including Alzheimer's, which can lead to the death of nerve cells. Selegiline is an antioxidant drug prescribed to patients with Parkinson's disease and in the present study as a drug for Alzheimer's treatment was used. Methods and Materials: In this study, 50 adult male rats were divided into 5 groups of 10. The control group received normal water and food for one month. The sham group received 5 microliters of phosphate salt buffer solution by intraventricular injection and then normal food and water for one month. The positive control group was gavaged with selegiline 5 mg/kg for one month and did not undergo surgery. The Alzheimer's group received 5 microliters of beta-amyloid solution by intraventricular injection and then plain water and food for one month. The treatment group received 5 μl of beta-amyloid solution by intraventricular injection and then 5 mg/kg of selegiline by gavage for one month. Memory, learning, and anxiety assessed by behavioral tests including navel object recognition, Morris water maze, and elevated plus maze, respectively. The results showed that memory and learning are impaired by intraventricular injection of beta-amyloid and also the level of anxiety increases. Results: Oral administration of selegiline significantly improves the effects of intraventricular injection of betaamyloid. Conclusion: Based on the findings of the present studies, it is believed that selegiline, due to its antioxidant properties, has a neuroprotective effect and can improve beta-amyloid disorders in memory, learning, and anxiety. [ABSTRACT FROM AUTHOR] |
